HIPK2 is a serine/threonine protein kinase that functions primarily as a tumor suppressor through p53-dependent and -independent mechanisms. At the molecular level, HIPK2 phosphorylates p53 and multiple transcriptional regulators (including ATF1, CREB1, RUNX1, and EP300) to promote apoptosis and inhibit cell growth 1. HIPK2 acts as a transcriptional corepressor of pro-survival factors like CTBP1 and β-catenin, promoting their proteasomal degradation [UniProt]. The kinase is regulated primarily through post-translational mechanisms: caspase-dependent processing hyperactivates HIPK2, while ubiquitin-proteasome system-mediated degradation inactivates it, with both processes controlled by p53 2. In disease contexts, HIPK2 shows context-dependent roles. Exercise downregulates cardiac HIPK2, protecting against myocardial infarction by reducing p53-mediated cardiomyocyte apoptosis 3, suggesting HIPK2 suppression may be cardioprotective. Conversely, in cancer, HIPK2 typically functions as an oncosuppressor, and its downregulation correlates with chemoresistance and poor prognosis 4. However, HIPK2 overexpression in HPV-positive tonsillar carcinomas associates with worse prognosis, indicating tumor context-dependent functions 5. HIPK2 is also implicated in neurological disorders through stress response pathways and is highly expressed in nervous systems 6. These multifaceted roles make HIPK2 a potential therapeutic target and prognostic biomarker across multiple disease states.